Study to assess immunogenicity, reactogenicity and safety of 1 dose of GSK Biologicals' MenACWY vaccine vs. 1 dose of Sanofi-Pasteur's Menactra in healthy subjects 10-25 years

Trial Profile

Study to assess immunogenicity, reactogenicity and safety of 1 dose of GSK Biologicals' MenACWY vaccine vs. 1 dose of Sanofi-Pasteur's Menactra in healthy subjects 10-25 years

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Jan 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 16 Oct 2007 Status changed from recruiting to in progress.
    • 14 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top